Preliminary data presented from phase I/II study of AGEN-1884 in combination with AGEN-2034 Oct. 30, 2018
CS-1001 demonstrates promising preliminary safety and antitumor activity in phase I study Oct. 30, 2018
Clearside Biomedical presents additional phase III data for Xipere in uveitic macular edema Oct. 30, 2018
Xtandi granted approval in Europe for high-risk nonmetastatic castration-resistant prostate cancer Oct. 30, 2018
RSS